Navidea Biopharmaceuticals (NASDAQ:NAVB)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Zacks.com reports.
Navidea Biopharmaceuticals (NASDAQ:NAVB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter. The firm had revenue of $0.24 million for the quarter.
Navidea Biopharmaceuticals Company Profile
Featured Article: What are the benefits of a portfolio tracker?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.